non-small cell lung cancer

Research Reports

Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer

12/15/2021

Helmy M Guirgis, MD, PhD

Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.

Helmy M Guirgis, MD, PhD, aimed...

12/15/2021

Journal of Clinical Pathways

Research Reports

Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival

10/21/2020

Lalan Wilfong, MD

Aimee Ginsburg, PharmD, BCPS

J Russell Hoverman, MD, PhD

John M Burke, MD

Leslie T Busby, MD

Angela Hsieh, PharmD, BCOP

Kartik Konduri, MD

Marcus A Neubauer, MD

Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...

...

10/21/2020

Journal of Clinical Pathways

Research Reports

Use of Biomarker Testing in Lung Cancer Among Puerto Rico and Florida Physicians: Results of a Comparative Study

10/18/2019

Teresita Muñoz-Antonia, PhD

Vani N Simmons, PhD

Steven K Sutton, PhD

Matthew B Schabath, PhD

Iffat Alam

Alberto Chiappori, MD

Gwendolyn P Quinn, PhD

Abstract: Biomarker-driven therapies are the gold standard of treatment in lung cancer. Recent studies suggest a higher prevalence of specific targetable biomarkers among Hispanic/Latinos (H/L) than non-Hispanic...

...

10/18/2019

Journal of Clinical Pathways

Research in Review

Time to Surgery After NCRT Affects NSCLC Survival

10/07/2016

JCP Editors

Patients with stage IIIA non-small cell lung cancer (NSCLC) who undergo surgery later than 6 weeks after neoadjuvant chemoradiation (NCRT) may experience significantly lower overall survival, according to results...

...

10/07/2016

Journal of Clinical Pathways

Department

PD-L1 Tests for NSCLC Differ in Effectiveness

09/28/2016

JCP Editors

A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...

A...

09/28/2016

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitor-Related Pneumonitis Most Common in NSCLC

09/23/2016

JCP Editors

Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...

...

09/23/2016

Journal of Clinical Pathways

Research in Review

No Difference in 5-Year Survival With Lung Cancer Staging Strategies

09/21/2016

JCP Editors

New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...

New...

09/21/2016

Journal of Clinical Pathways

Research in Review

Dose Adjustment Reduces AEs Without Impacting Efficacy in NSCLC

09/14/2016

JCP Editors

Tolerability-guided dose adjustment is an effective measure to reduce afatinib (Giotrif)-related adverse events (AEs) without affecting therapeutic efficacy in patients with non–small cell lung cancer (NSCLC),...

...

09/14/2016

Journal of Clinical Pathways

Research in Review

Little Survival Benefit from WBRT in NSCLC Patients With Brain Metastasis

09/08/2016

JCP Editors

Patients with non-small cell lung cancer and brain metastasis can be spared whole brain radiotherapy (WBRT), as it does little or has no effect on survival and quality of life, according to a study published in The...

...

09/08/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz ‚Äì Week of August 15-21

08/18/2016

JCP Editors

A recent study of non-small cell lung cancer found that those with epidermal growth factor receptor (EGFR)-positive disease were at an increased likelihood of developing leptomeningeal metastases (LM), but that...

A...

08/18/2016

Journal of Clinical Pathways